Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat 3 Undervalued Names Too Cheap to IgnoreBy Nathan Reiff. First Published: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: Elon Musk already made me a "wealthy man"
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, several sizable firms are trading at attractive valuations and could offer upside from both share-price appreciation and fundamental growth. The companies below represent potential value plays, based on historically low metrics and/or competitiveness relative to peers or the broader market. They also offer additional benefits such as compelling dividends or promising new products. While value opportunities can be harder to find when many companies have already drawn investor attention — and some apparent bargains carry operational red flags — well-established, stable names can still be attractive value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works San Francisco is the strangest city in America right now—you can hop into a self-driving car and be chauffeured by a robot, but out the window you see addicts slumped in doorways, open-air drug markets, the mentally ill screaming at the sky, and entire city blocks consumed by homeless encampments. It's ground-zero for the most disruptive technological forces of our age, and Erez lives in the Bay Area plugged into the capital, the connections, and the companies reshaping the world—the advancements in AI, blockchain, computing, and biosciences are unlike anything the world has seen before, and a tsunami of disruption is coming for everything all at once. During our most recent broadcast, we exposed what we're calling the most asymmetric opportunity of our careers: an overlooked financial company hiding a multi-billion-dollar blockchain asset Wall Street hasn't priced in—it's one of those rare situations Warren Buffett would describe as raining gold when all you have to do is step outside if you want to get rich. Watch the broadcast before the window closes now Although shares have climbed more than 28% in the past year, bringing Merck's market capitalization to nearly $300 billion, Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45 — well below the medical industry average of roughly 27. Analysts expect continued growth: earnings are projected to rise nearly 10% in the coming year, and the stock shows about 5% additional upside in the near term. Fueling Merck's momentum is its pembrolizumab cancer drug, Keytruda, which received European Commission approval for subcutaneous injection in late 2025 and generated about $8.4 billion in sales in Q4 2025 — up roughly 7% year over year. Keytruda also shows promise in ovarian cancer, potentially expanding its patient base as the company prepares for patent expiration in 2028. Merck's portfolio is broadening beyond oncology. The company recently released phase 3 results for clesrovimab, marketed as Enflonsia, an RSV treatment for young children. At the same time, Merck is reorganizing its human health division into two units to facilitate growth in non-cancer products and better position itself for the post-Keytruda landscape. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) shares have fallen about 37% over the past year as the food-and-beverage staple contends with tariffs and inflation. In Q1 fiscal 2026 (ended Nov. 2, 2025), the company reported modest year-over-year declines in organic net sales and consumption, and adjusted EPS fell 13% over the same period. Cost-saving measures have not yet produced significant margin improvement. The near term is likely to remain challenging, with weak fiscal-year guidance overall. However, improving supply-chain capabilities and strong brand loyalty — particularly for premium offerings — should provide some protection. Additionally, shifts in tariff policies could ease pressure on the company's results. Campbell's remains a noteworthy dividend play, offering a 5.9% yield, though its payout ratio exceeds 80%. Its P/E ratio of 13.5 is the lowest in about four years, which may attract investors willing to accept short-term risks for potential long-term rewards despite Wall Street caution. A Recent US Foods Rally May Continue as Bottom-Line Growth Remains in Place Foodservice distributor US Foods (NYSE: USFD) has had an almost opposite trajectory to Campbell's — shares climbed roughly 33% over the last year. Still, its P/E ratio sits at 31.6, which is moderate compared with many high-growth names. Fundamentally, US Foods is making progress: the company reported improved profitability in the latest quarter and full-year adjusted EBITDA gains of 11% year over year. Better inventory management and cost-of-goods improvements are helping the firm gain traction. With a $4 billion capital deployment plan, US Foods is positioned to sustain revenue momentum and continue growing adjusted EBITDA. Analysts rate USFD a Moderate Buy based on 11 Buys and 2 Holds, implying roughly 15% upside potential. | 
